science

UB-612

UB-612 is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand UB-612 rather than just read about it. In short: UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.

Key takeaways

UB-612 belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect UB-612 to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of UB-612 from memory before moving on to harder problems.

Reference excerpt

UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine. It is composed of SARS-CoV-2 S1-RBD protein and synthetic peptides representing T cell (Th and CTL) epitopes on the nucleocapsid, spike and membrane proteins. The multitope composition is differentiated from other solely spike-protein based vaccines. By recognition against epitopes on Spike (S1-RBD and S2) and non-Spike (N and M) structure proteins, UB-612 provides B-cell and T-cell memory immunity and offers a potential as a universal vaccine to fend off the Omicron variant and new emerging variants of concern. Vaxxinity began seeking regulatory approval for UB-612 for use as a booster vaccine in the United Kingdom and Australia in 2022.

Technology UB-612 is a peptide vaccine incorporating multiple epitopes, including the spike protein receptor binding domain as well as other virus structural proteins. The spike protein peptide is fused to an Fc domain of single-chain IgG1, and the other six peptides are derived from highly conserved sequences from the spike, nucleocapsid, and membrane proteins of SARS-CoV-1 and SARS-CoV-2. It also contains a proprietary UBITh1 peptide derived from the measles virus fusion protein, CpG oligonucleotides, and aluminum phosphate adjuvant to improve the immune response. It is produced in CHO cells.

Clinical trials In September 2020, phase I clinical trials of UB-612 started in Taiwan. and in January 2021, phase II clinical trials began in Taiwan. In February 2021, phase II/III clinical trials began. Results from clinical trials showing positive safety and efficacy data were published in May 2022, and in May-June 2023. In March 2022, Vaxxinity started an international phase III clinical trial of UB-612 as a heterologous booster vaccine against three approved platforms: mRNA, adenovirus vector, and inactivated virus. The company announced positive topline data of the trial in December 2022 and positive results were published in January 2024. A Phase III international trial conducted from March to September 2023, found that UB‑612, given as a heterologous third‑dose booster after primary vaccines, met non‑inferiority versus homologous boosters, outperformed ChAdOx1 and Sinopharm BIBP COVID-19 vaccines on neutralizing antibody responses (including Omicron subvariants), showed durability comparable to Pfizer–BioNTech COVID-19 vaccine through 12 months, and had a similar safety profile.

Controversy In June 2021, a report revealed that the UB-612 vaccine was developed in part by the US-based Covaxx, a for-profit venture initiated by Blackwater founder Erik Prince. In a series of text messages to Paul Behrends, the close associate recruited for the Covaxx project, Prince described the profit-making possibilities of selling the COVID-19 vaccines. At the time, Covaxx had not yet provided any data from the clinical trials on safety or efficacy it conducted in Taiwan. The responsibility of creating distribution networks was assigned to an Abu Dhabi-based entity, which was mentioned as "Windward Capital" on the Covaxx letterhead but was actually Windward Holdings. The firm's sole shareholder, who handled "professional, scientific and technical activities", was Erik Prince. In March 2021, Covaxx raised $1.35 billion in a private placement.

References

Illustrations

Worked examples

Example 1 — a first encounter with UB-612

Start with the simplest possible case. Write down what UB-612 claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to UB-612 before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about UB-612 ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of UB-612

In research: UB-612 appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses UB-612 in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: UB-612 is common in secondary-school and first-year university syllabi. It links to neighbouring topics Clinical trials related to COVID-19, Peptide vaccines, Taiwanese COVID-19 vaccines, so understanding it makes those chapters shorter.
In everyday life: Look for UB-612 outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “UB-612” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study UB-612 in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what UB-612 means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain UB-612 out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is UB-612 in simple terms?

UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.

Why does UB-612 matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study UB-612?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on UB-612.